Ebos's 1H Result Probably Enough to Rebuild Investor Confidence -- Market Talk

Dow Jones

02/26

0226 GMT - Forsyth Barr says pharmacy chain owner Ebos's 1H result was in line with its expectations, but by no means perfect. Community Pharmacy revenue beat consensus hopes. Contract Logistics growth was strong, while retaining FY 2026 guidance was another positive, Forsyth Barr says. It says negatives are the low quality of earnings, weak cash flow, and a miss on Community Pharmacy margins. "Overall, we think the result has done enough to provide the building blocks to rebuild investor confidence and meaningfully reduces the downside risks from here, but it will not be an overnight fix," analyst Matt Montgomerie says. Ebos is down 0.3% at NZ$24.02 today. Forsyth Barr retains an outperform call on the stock and trims its price target by 3.9% to NZ$35.80/share. (david.winning@wsj.com; @dwinningWSJ)

(END) Dow Jones Newswires

February 25, 2026 21:26 ET (02:26 GMT)

应版权方要求，你需要登录查看该内容

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2614064103"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2614064103\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2614064103?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-02-26 10:26","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2614064103","market":"other","top_or_hot":-1,"title":"Ebos's 1H Result Probably Enough to Rebuild Investor Confidence -- Market Talk","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n     0226 GMT - Forsyth Barr says pharmacy chain owner Ebos's 1H result was in line with its expectations, but by no means perfect. Community Pharmacy revenue beat consensus hopes. Contract Logistics growth was strong, while retaining FY 2026 guidance was another positive, Forsyth Barr says. It says negatives are the low quality of earnings, weak cash flow, and a miss on Community Pharmacy margins. \"Overall, we think the result has done enough to provide the building blocks to rebuild investor confidence and meaningfully reduces the downside risks from here, but it will not be an overnight fix,\" analyst Matt Montgomerie says. Ebos is down 0.3% at NZ$24.02 today. Forsyth Barr retains an outperform call on the stock and trims its price target by 3.9% to NZ$35.80/share. (david.winning@wsj.com; @dwinningWSJ) \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  February 25, 2026 21:26 ET (02:26 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Ebos's 1H Result Probably Enough to Rebuild Investor Confidence -- Market Talk</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nEbos's 1H Result Probably Enough to Rebuild Investor Confidence -- Market Talk\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2026-02-26 10:26</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n     0226 GMT - Forsyth Barr says pharmacy chain owner Ebos's 1H result was in line with its expectations, but by no means perfect. Community Pharmacy revenue beat consensus hopes. Contract Logistics growth was strong, while retaining FY 2026 guidance was another positive, Forsyth Barr says. It says negatives are the low quality of earnings, weak cash flow, and a miss on Community Pharmacy margins. \"Overall, we think the result has done enough to provide the building blocks to rebuild investor confidence and meaningfully reduces the downside risks from here, but it will not be an overnight fix,\" analyst Matt Montgomerie says. Ebos is down 0.3% at NZ$24.02 today. Forsyth Barr retains an outperform call on the stock and trims its price target by 3.9% to NZ$35.80/share. (david.winning@wsj.com; @dwinningWSJ) \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  February 25, 2026 21:26 ET (02:26 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK8046","symbol_name":"保健护理产品经销商","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2614064103","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2614064103","pubTimestamp":1772072760,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"0226 GMT - Forsyth Barr says pharmacy chain owner Ebos's 1H result was in line with its expectations, but by no means perfect. Community Pharmacy revenue beat consensus hopes. Contract Logistics growth was strong, while retaining FY 2026 guidance was another positive, Forsyth Barr says. It says negatives are the low quality of earnings, weak cash flow, and a miss on Community Pharmacy margins. \"Overall, we think the result has done enough to provide the building blocks to rebuild investor confidence and meaningfully reduces the downside risks from here, but it will not be an overnight fix,\" analyst Matt Montgomerie says. Ebos is down 0.3% at NZ$24.02 today. Forsyth Barr retains an outperform call on the stock and trims its price target by 3.9% to NZ$35.80/share. ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK8046":"保健护理产品经销商","EBO.NZ":"Ebos Group Limited Ordinary Shares","EBO.AU":"EBOS GROUP LIMITED","BK7103":"保健护理产品经销商"},"translate_title":"Ebos上半年业绩可能足以重建投资者信心——市场讨论","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"EBO.NZ":0.9,"EBO.AU":0.9},"content_text":"0226 GMT - Forsyth Barr says pharmacy chain owner Ebos's 1H result was in line with its expectations, but by no means perfect. Community Pharmacy revenue beat consensus hopes. Contract Logistics growth was strong, while retaining FY 2026 guidance was another positive, Forsyth Barr says. It says negatives are the low quality of earnings, weak cash flow, and a miss on Community Pharmacy margins. \"Overall, we think the result has done enough to provide the building blocks to rebuild investor confidence and meaningfully reduces the downside risks from here, but it will not be an overnight fix,\" analyst Matt Montgomerie says. Ebos is down 0.3% at NZ$24.02 today. Forsyth Barr retains an outperform call on the stock and trims its price target by 3.9% to NZ$35.80/share. (david.winning@wsj.com; @dwinningWSJ) \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  February 25, 2026 21:26 ET (02:26 GMT)\n\n\n  Copyright (c) 2026 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}